Data from a clinical trial involving University of California, Los Angeles researchers suggest that a new therapy may potentially serve as a "functional cure" for HIV/AIDS. The therapy, called SB-728-T, involves the modification of both copies of a patient's CCR5 gene, which encodes the major co-receptor used by HIV to infect immune system cells.
Purdue University is part of a national institute that received a grant of up to $35 million over the next five years from the U.S. Food and Drug Administration (FDA). The FDA awarded the grant to the National Institute for Pharmaceutical Technology and Education, or NIPTE, to improve manufacturing standards and ultimately cut health care costs, create jobs, and improve drug safety.
Researchers at Rutgers University and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles.
Anti-caking agents in powdered products may hasten degradation of vitamin C instead of doing what they are supposed to do: protect the nutrient from moisture. A Purdue University team is studying deliquescence, a reaction in which humidity causes a crystalline solid to dissolve, in hopes to understand how anti-caking agents protect substances such as vitamin C from humidity.
Southwest Research Institute was awarded a $4.4 million contract from the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority to develop a nasal-delivery, first-line treatment system to combat cyanide poisoning.
The blood from woolly mammoths—those extinct elephant-like creatures that roamed the Earth in pre-historic times—is helping scientists develop new blood products for modern medical procedures that involve reducing patients’ body temperature.
A team of researchers from the University of Houston and St. Luke’s Episcopal Hospital are working to develop improved screening methods to detect a potentially lethal, drug-resistant superbug that has made its way to Texas.
Chiesi Farmaceutici and NiKem Research have announced details of their extended research collaboration within the respiratory therapeutic area. The current extension involves the period 2011 to 2014 through a multimillion multi-FTE-based service agreement on pre-clinical projects of interest for Chiesi in the repiratory therapeutic area focused on pathologies such as asthma and COPD.
Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the laboratory. The compound, which occurs naturally in a species of moss found in China, is an enzyme inhibitor that has been used to treat Alzheimer's disease in China since the late 1990s and is sold in the U.S. as a dietary supplement to help maintain memory.
Cresset and Redx Pharma announced that they have signed a major drug discovery collaboration, which gives Redx Pharma access to Cresset's computational chemistry technologies for use on their portfolio of drug discovery programs.
In a new study, University of Wisconsin-Madison researchers have described a simple process to separate sugars from a carrier molecule, then attach them to a drug or other chemical.
It is helpful—even life-saving—to have a warning sign before a structural system fails, but, when the system is only a few nanometers in size, having a sign that's easy to read is a challenge. Now, thanks to scientists from the University of Pennsylvania and Duke University, such warning can come in the form of a simple color change.
A team of Swinburne University of Technology researchers has shown that low-temperature microwaves can be used to open up pores in bacterial cells, which could lead to significant improvements in the design of drug delivery systems.
In an advance that could broadly expand the possible applications for microparticles, Massachusetts Institute of Technology engineers have developed a way to make microparticles of nearly any shape, using a micromold that changes shape in response to temperature.
The last century has seen two major pandemics caused by the H1N1 virus—the Spanish flu in 1918 and the swine flu scare of 2009. But scientists did not know what distinguished the swine flu from ordinary influenza in pigs or seasonal outbreaks in humans, giving it the power to travel extensively and infect large populations. Until now.
Most bacterial infections can be treated with antibiotics such as penicillin. However, such drugs are useless against viral infections. Now, in a development that could transform how viral infections are treated, a team of researchers at the Massachusetts Institute of Technology's Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
An international team of researchers has shown a derivative of a common culinary spice found in Indian curries could offer a new treatment hope for sufferers of the painful condition tendinitis.
Researchers at the California Institute of Technology have applied a relatively simple engineering technique to boost the battling prowess of an algae-sourced protein, called cyanovirin-N, that has gained attention for its antiviral properties.
The University of Michigan's Consortium for Stem Cell Therapies has achieved another of its primary goals: reprogramming adult skin cells so they behave like embryonic stem cells. The reprogrammed cells are called induced pluripotent stem cells, or iPs cells.
LEUKOCARE AG, a privately-owned specialist company for protein stabilization and biological surface coating, announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi. As part of this cooperation, Sanofi Pasteur will explore LEUKOCARE’s SPS platform technology to enhance the shelf-life of selected vaccine formulations.
The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol fighter Lipitor and blood thinner Plavix. Generic competition will decimate sales of the brand-name drugs and cut costs to patients and companies that provide health benefits.
Researchers at Duke University Medical Center have discovered a way to block the damaging actions of chlamydia. The team, which included Duke University microbiologists and chemists, designed a molecule that takes away the bacteria's self-defense mechanisms.
The Siemens Healthcare Diagnostics D-dimer assay for the company's Stratus CS Acute Care Diagnostic System has been cleared by the FDA to exclude pulmonary embolism in conjunction with a non-high clinical pretest probability assessment model in point-of-care.
A study involving researchers at Caltech points to the possibility of using neutralizing antibodies in the development of a vaccine for HIV. Their research describes a group of novel antibodies that were isolated from HIV-infected individuals using a new cloning approach.
A breakthrough in sensing at Rice University could make finding signs of Alzheimer's disease nearly as simple as switching on a light. The technique should help researchers design better medications to treat the devastating disease.